No standard treatment has been established for metastatic uveal melanoma (mUM).
Immunotherapy is commonly used for this disease even though UM has not been included …

Background: Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …

Background: Uveal melanoma is the most common primary intraocular malignancy among
adults. It is, nevertheless, a rare disease, with an incidence of approximately one case per …

Introduction Uveal melanoma (UM) is the most common intraocular cancer and represents a
discrete subtype of melanoma. Metastatic disease, which occurs in half of patients, has a …

Uveal melanoma is the most prevalent primary intraocular tumour in adults with the
incidence between five and six cases per million people in the United States and Europe …

Uveal melanoma is an intraocular malignancy that, depending on its size and genetic make-
up, may lead to metastases in up to 50% of cases. Currently, no therapy has been proven to …

Background Uveal melanoma (UM) is the most common intraocular malignancy in adults. In
contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and …

Uveal melanoma (UM) is one of the rare malignancies, which can be lethal despite local
treatment. Treatment options available now can control UM in early stages, but once it …

Background. Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a
median overall survival (OS) of 4–15 months. Despite new insights into the genetic and …

Background No standard treatment has been defined for metastatic uveal melanoma (mUM).
Although clinical trials testing Nivolumab/Pembrolizumab for cutaneous melanoma did not …